Centessa board adds ex-BMS regulatory exec; director Kantoff resigns

Centessa Pharmaceuticals plc

Aaron Kantoff resigned from Centessa board effective July 1, 2022; no disagreement cited, will remain as advisor.
Mathias Hukkelhoven, former SVP Global Regulatory at BMS, appointed to board and Nominating & Governance Committee.
Hukkelhoven receives initial option for 96,000 ordinary shares vesting over 3 years, plus annual grants of 48,000 shares.
Dr. Hukkelhoven also serves on Compugen (CGEN) board and as advisor to McKinsey and LianBio.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mathias Hukkelhoven

director

CNTA · Centessa Pharmaceuticals plc

Effective: 2022-07-01
Filed: July 1, 2022, 7:59 PM ET

On July 1, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Mathias Hukkelhoven, Ph.D. to join the Board, effective immediately.

Departed

Aaron Kantoff

director

CNTA · Centessa Pharmaceuticals plc

Effective: 2022-07-01
Filed: July 1, 2022, 7:59 PM ET

On July 1, 2022, Aaron Kantoff, a member of the board of directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company”) , notified the Company of his resignation from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mathias Hukkelhoven was appointed as director at Centessa Pharmaceuticals plc.

Action: appointed
Role: director

Exact text from the filing

On July 1, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Mathias Hukkelhoven, Ph.D. to join the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Aaron Kantoff resigned as director at Centessa Pharmaceuticals plc.

Action: resigned
Role: director

Exact text from the filing

On July 1, 2022, Aaron Kantoff, a member of the board of directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company”) , notified the Company of his resignation from the Board, effective immediately.

View on SEC.gov

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-22-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.